[Federal Register Volume 69, Number 189 (Thursday, September 30, 2004)]
[Notices]
[Page 58541]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 04-21944]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to 21 CFR 1301.33(a), this is a notice that on June 10, 
2004 Aldrich Chemical Company Inc., DBA Isotec, 3858 Benner Road, 
Miamisburg, Ohio 45342-4304, made application by renewal to the Drug 
Enforcement Administration (DEA) for registration as a bulk 
manufacturer of the basic classes of controlled substances listed:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Cathinone (1235)...........................  I
Methcathinone (1237).......................  I
N-Ethylamphetamine (1475)..................  I
N,N-Dimethylamphetamine (1480).............  I
Aminorex (1585)............................  I
Gamma hydroxybutyric acid (2010)...........  I
Methaqualone (2565)........................  I
Lysergic acid dethylamide (7315)...........  I
Tetrahydrocannabinols (7370)...............  I
Mescaline (7381)...........................  I
2,5-Dimethoxyamophetamine (7396)...........  I
3,4-Methylenedioxyamphetamine (7400).......  I
3,4-Methylenedioxy-N-ethylamphetamine        I
 (7404).
3,4-Methylenedioxy-methamphetamine (7405)..  I
4-Methoxyamphetamine (7411)................  I
Psilocybin (7437)..........................  I
Psilocyn (7438)............................  I
N-Ethyl-1-phenylcyclohexalamine (7455).....  I
Dihydromorphine (9145).....................  I
Normorphine (9313).........................  I
Acetylmethadol (9601)......................  I
Alphacetylmethadol Except Levo-              I
 Alphacetylmethadol (9603).
Normethadone (9635)........................  I
3-Methylfentanyl (9813)....................  I
Amphetamine (1100).........................  II
Methamphetamine (1105).....................  II
Methylphenidate (1724).....................  II
Amobarbital (2125).........................  II
Pentobarbital (2270).......................  II
Secobarbital (2315)........................  II
1-Phenylcyclohexalamine (7460).............  II
Phencyclidine (7471).......................  II
Phenylacetone (8501).......................  II
1-Piperidinocyclohexane-carbonitrile (8603)  II
Codeine (9050).............................  II
Dihydrocodeine (9120)......................  II
Oxycodone (9143)...........................  II
Hydromorphone (9150).......................  II
Benzoylecgonine (9180).....................  II
Ethylmorphine (9190).......................  II
Hydrocodone (9193).........................  II
Isomethadone (9226)........................  II
Meperidine (9230)..........................  II
Meperidine intermediate-A (9232)...........  II
Meperidine intermediate-B (9233)...........  II
Methadone (9250)...........................  II
Methadone intermediate (9254)..............  II
Dextropropoxyphene, bulk, (non-dosage        II
 forms) (9273).
Levo-alphacetylmethadol (9648).............  II
Oxymorphone (9652).........................  II
Fentanyl (9801)............................  II
------------------------------------------------------------------------

    The company plans to manufacture small quantities of the listed 
controlled substances to produce isotope labeled standards for drug 
analysis.
    Any other such applicant and any person who is presently registered 
with DEA to manufacture such a substance may file comments or 
objections to the issuance of the proposed registration pursuant to 21 
CFR 1301.33(a).
    Any such comments or objections may be addressed, in quintuplicate, 
to the Deputy Assistant Administrator, Office of Diversion Control, 
Drug Enforcement Administration, United States Department of Justice, 
Washington, DC 20537, Attention: DEA Federal Register Representative 
(CCD) and must be filed no later than (60 days from publication).

    Dated: September 16, 2004.
William J. Walker,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 04-21944 Filed 9-29-04; 8:45 am]
BILLING CODE 4410-09-M